Dose escalation of lobaplatin combined with fixed docetaxel in second-line chemotherapy with solid tumors

刘月娥; 任小沧; 陈雪霁

doi:10.3969/j.issn.1007-3969.2015.03.009

您当前的位置：

首页 >

文章列表页 >

Dose escalation of lobaplatin combined with fixed docetaxel in second-line chemotherapy with solid tumors

更新时间：2025-12-31

- Dose escalation of lobaplatin combined with fixed docetaxel in second-line chemotherapy with solid tumors
- China Oncology Vol. 25, Issue 3, Pages: 211-216(2015)
- 作者机构：
  
  河北医科大学附属华北石油管理局总医院肿瘤科，河北任丘,062552
- 作者简介：
- 基金信息：
- DOI：10.3969/j.issn.1007-3969.2015.03.009
  CLC：
- Published Online：18 May 2015，
  
  Published：18 May 2015
- 稿件说明：
移动端阅览
刘月娥,任小沧,陈雪霁,等. 洛铂联合固定剂量多西紫杉醇二线及以上治疗晚期实体肿瘤的剂量递增研究[J]. 中国癌症杂志, 2015, 25(3): 211-216.

刘月娥, 任小沧, 陈雪霁. Dose escalation of lobaplatin combined with fixed docetaxel in second-line chemotherapy with solid tumors[J]. China Oncology, 2015, 25(3): 211-216.
刘月娥,任小沧,陈雪霁,等. 洛铂联合固定剂量多西紫杉醇二线及以上治疗晚期实体肿瘤的剂量递增研究[J]. 中国癌症杂志, 2015, 25(3): 211-216. DOI： 10.3969/j.issn.1007-3969.2015.03.009.

刘月娥, 任小沧, 陈雪霁. Dose escalation of lobaplatin combined with fixed docetaxel in second-line chemotherapy with solid tumors[J]. China Oncology, 2015, 25(3): 211-216. DOI： 10.3969/j.issn.1007-3969.2015.03.009.

摘要

背景与目的：恶性肿瘤一线化疗后多出现复发或转移，需要二线及以上治疗。本研究旨在确定洛铂联合固定剂量多西紫杉醇治疗化疗后进展的实体肿瘤时洛铂的最大耐受剂量(maximum-tolerated dose，MTD)，并评价其不良反应。方法：应用改良的Fibonacci法进行洛铂剂量递增，固定多西紫杉醇剂量为60 mg/m

，洛铂初始剂量为30 mg/m

，组间递增剂量为5 mg/m

，每21天重复。每组至少3例，如1个剂量组中3例均无剂量限制性毒性(dose-limiting toxicity，DLT)出现，则进入下1个剂量组，直至出现DLT，DLT的低一剂量水平即为MTD。结果：17例患者共完成58个周期化疗，进行3个剂量组的研究(洛铂分别为30、35、40 mg/m

)，完全缓解(complete response，CR)0例，部分缓解(partial response，PR)1例，疾病稳定(stable disease，SD)10例，疾病进展(progression disease，PD)3例；有效率(response rate，RR，CR+PR)为7.1%(1/14)，疾病控制率(disease control rate，DCR，CR+PR+SD)为78.6%(11/14)。主要不良反应为白细胞下降，3例出现DLT，其中2例发生在洛铂40 mg/m

组。确定洛铂35 mg/m

组为MTD。结论：本组洛铂联合固定剂量多西紫杉醇的MTD为35 mg/m

，其不良反应可耐受。

Abstract

Background and purpose: Malignant tumors often relapsed or metastasized after first-line chemotherapy and needed second-line or above treatment. We conducted this study to define the maximum-tolerated dose (MTD) of lobaplatin with fixed docetaxel for Chinese patients in previously treated solid tumors. Methods: Escalating doses of lobaplatin with fixed docetaxel were administered in a modified Fibonacci sequence. The initial doses were lobaplatin 30 mg/m

and

docetaxel 60 mg/m

respectively. Escalating doses was 5 mg/m

. The regimen was repeated every 21 days. If no dose-limiting toxicity (DLT) was observed

the next dose level was applied. The procedures were repeated until DLT appeared. The MTD was declared to be one dose level below the level at which DLT appeared. Results: Seventeen patients received fifty-eight cycles chemotherapy at lobaplatin of level Ⅰ (30mg/m

)

level Ⅱ (35 mg/m

)and level Ⅲ(40 mg/m

). Cases of complete response (CR)

partial response (PR)

stable disease (SD) and progression disease (PD) for the whole group were 0

10 and 3

respectively. Response rate (RR

CR+PR) and disease control rate (DCR

CR+PR+SD) were 7.1% (1/14) and 78.6% (11/14)

respectively. The most common toxicity was leukopenia. Three DLTs occurred in 3 patients in the whole group

including 2 DLTs in dose level Ⅲ. We declared thus level Ⅱ was MTD. Conclusion: MTD of lobaplatin in our research was 35 mg/m

combined with fixed dose of docetaxel. This combination regimen was well tolerated.

关键词

Keywords

references

Views

2880

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Research progress on treatment of pleural effusion related to immune checkpoint inhibitors

A prospective single-arm study of the efficacy and safety of lobaplatin-based HIPEC combined with optimal support in the treatment of abdominal metastatic cancer

A study of relationship between cardiac exposure dose-volume and cardiovascular autonomic dysfunction in radiotherapy

Research progress and future perspectives of tumor organoid

Application progress of oncolytic virus combined with immunotherapy in the treatment of malignant tumors

Related Author

Yun YANG

Jianhui TIAN

Tianqi AN

Yiyang ZHOU

Bin LUO

Zujun QUE

Yao LIU

Pan YU

Related Institution

Department of Oncology, The First Affiliated Hospital of Zhengzhou University

Clinical Oncology Center, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Institute of Oncology, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine

Department of Oncology, Shanghai Tenth People's Hospital, Tongji University School of Medicine

Department of Radiotherapy, Affiliated Hospital of North China University of Science and Technology

Mengchao Hepatobiliary Hospital of Fujian Medical University

AI问答

⁰